2023 will be a critical year for the success of biosimilar uptake and patient access.
Biosimilar launches are growing at a steady pace — but they are still not readily prescribed.
Despite the number of product launches, biosimilar adoption in the U.S. has been deficient, especially compared to Europe. Since 2007, 30 biosimilars for 12 lar
27-28 June 2023